An open-label, randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, vers. Platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent NSCLC

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.